NAD+ Dosage Guide: IV, Injection, and Oral Protocols Compared

NAD+ dosage depends on the route: IV NAD+ is usually given at 250 to 1,500 mg per session (250 to 500 mg for general wellness), subcutaneous injections at 50 to 200 mg two to three times per week, and the oral precursors NMN at 250 to 1,000 mg per day or NR at 250 to 600 mg per day. None of these ranges is an FDA approved dose; they are clinic and research protocols, and the oral ranges come from human trials such as Martens et al. (2018) for NR and Yoshino et al. (2021) for NMN.

NAD+ (nicotinamide adenine dinucleotide) is one of the most talked-about molecules in longevity and regenerative medicine. It plays a central role in cellular energy production, DNA repair, sirtuin activation, and hundreds of other enzymatic reactions. NAD+ levels decline with age, and that decline is linked to many of the hallmarks of aging: mitochondrial dysfunction, increased inflammation, impaired DNA repair, and metabolic slowdown [1].

The treatment question is not whether NAD+ matters. That is well established at the molecular level. The question is how to get it back up. IV infusions deliver NAD+ directly into the bloodstream. Subcutaneous injections offer a faster, cheaper alternative. Oral supplements (NMN and NR) provide a daily maintenance option. Each route has different dosing protocols, bioavailability profiles, costs, and evidence behind it.

NAD+ dosing protocols differ by delivery route, by phase (loading versus maintenance), and by the condition a clinician is targeting. Each is compared side by side below, followed by condition-specific approaches and the questions patients ask most often.

Why Delivery Method Matters

NAD+ is a large molecule. When you take it orally, it gets broken down in the gut before reaching the bloodstream. That is why oral supplements use NAD+ precursors (NMN and NR) rather than NAD+ itself. These smaller molecules survive digestion, get absorbed, and are then converted into NAD+ inside cells through enzymatic pathways [2].

IV and injection routes bypass the gut entirely, delivering NAD+ (or close to it) directly into the bloodstream. This means higher immediate bioavailability but also higher cost and less convenience.

Delivery Method	What You Receive	Bioavailability	Cost per Dose	Convenience
IV infusion	Pure NAD+	100% (direct to blood)	$250 to $1,000+	Low (clinic visit, 2 to 4 hours)
SubQ injection	NAD+ solution	High (bypasses gut)	$25 to $75	Moderate (self-inject at home)
Oral NMN	NAD+ precursor	Variable (gut absorption + conversion)	$1 to $3	High (daily capsule)
Oral NR	NAD+ precursor	Variable (gut absorption + conversion)	$1 to $2	High (daily capsule)

NAD+ Dosage at a Glance: Doses by Route

The usual NAD+ dosage is 250 to 500 mg per IV session for general wellness, 100 to 200 mg per subcutaneous injection, 250 to 1,000 mg per day of oral NMN, or 250 to 600 mg per day of oral NR. The table below restates the ranges used throughout this guide, with how often each is typically given.

Clinicians who prescribe NAD+ include integrative and functional medicine physicians, nurse practitioners and physician assistants at infusion clinics, and addiction medicine teams. Registered nurses usually place the IV line and adjust the drip rate. To compare providers who offer infusions, browse the directory of NAD+ IV therapy clinics, where listing order is not paid ranking.

IV NAD+ Dosing Protocols

IV NAD+ is the most direct method and the one used in most clinical settings for therapeutic purposes. The NAD+ molecule goes straight into your bloodstream, bypassing digestion entirely.

NAD+ IV therapy dosage ranges from 250 to 1,500 mg per session. The dose is set by the goal of treatment and by how well the patient tolerates the drip, and higher doses take proportionally longer to infuse. The NAD+ IV therapy treatment guide covers how the infusion works and who tends to seek it.

Standard Dosing Ranges

• General wellness / anti-aging: 250 to 500 mg per session
• Cognitive support / brain fog: 500 to 750 mg per session
• Neurological conditions (TBI, neurodegeneration): 750 to 1,000 mg per session
• Addiction recovery: 1,000 to 1,500 mg per session (often daily for 7 to 10 days)
• Chronic fatigue / long COVID: 500 to 750 mg per session

What is a starter NAD+ IV dose?

A starter NAD+ IV dose is usually 250 mg, infused over 1.5 to 2 hours. Clinics often call this a starter or introductory drip because it lets the nurse find the patient's tolerance threshold before moving to 500 mg or more. Patients who tolerate 250 mg comfortably are typically stepped up at later sessions rather than within the same visit.

Infusion Duration and Rate

NAD+ IV infusions are slow by design. The molecule causes dose-dependent side effects when infused too quickly: chest tightness, nausea, flushing, and a general feeling of discomfort that patients describe as “the NAD flush.” These symptoms are not dangerous but they are unpleasant [3].

Typical infusion times:

• 250 mg: 1.5 to 2 hours
• 500 mg: 2 to 3 hours
• 750 mg: 3 to 4 hours
• 1,000 mg: 4 to 6 hours
• 1,500 mg: 6 to 8 hours (sometimes split across two days)

The infusion rate is typically adjusted based on patient tolerance. Most clinics start slow and increase the drip rate until the patient reports the first signs of discomfort, then back off slightly. First-time patients should expect longer sessions as the provider finds their tolerance threshold.

Loading vs. Maintenance Protocols

Most practitioners use a two-phase approach:

Loading phase: A concentrated initial series to rapidly restore NAD+ levels. Common protocols include 4 to 6 infusions over 1 to 2 weeks, or 3 infusions in a single week. Addiction recovery protocols often use daily infusions for 7 to 10 consecutive days at 1,000 to 1,500 mg [3].

Maintenance phase: After loading, most patients transition to monthly or quarterly infusions at 250 to 500 mg to sustain levels. Some patients maintain with SubQ injections or oral precursors between IV sessions to reduce cost.

Clinic pricing varies by region and by dose, and the breakdown of NAD+ IV therapy cost explains what usually drives the bill.

How Often Should You Get NAD+?

NAD+ frequency depends on the phase and the route. A loading phase usually means 3 to 6 IV sessions over 1 to 2 weeks, maintenance usually means one IV session per month or per quarter, subcutaneous injections are given 2 to 3 times per week, and oral NMN or NR is taken every day.

• IV loading: 4 to 6 infusions over 1 to 2 weeks, or 3 infusions in a single week
• IV maintenance: 250 to 500 mg monthly or quarterly
• Addiction protocols: daily IV infusions for 7 to 10 days, then a step-down schedule under clinical supervision
• SubQ injections: 100 to 200 mg, 2 to 3 times per week
• Oral precursors: once daily (NMN) or once to twice daily (NR)

No controlled trial has compared IV schedules head to head, so these intervals reflect clinic practice rather than tested outcomes. A prescriber should set the frequency and review it if symptoms or side effects change.

Subcutaneous NAD+ Injection Dosing

SubQ NAD+ injections have gained popularity as a middle ground between IV infusions and oral supplements. You inject a small volume of NAD+ solution into the fatty tissue of the abdomen or thigh, similar to how diabetics inject insulin.

Standard Dosing

• Starting dose: 50 to 100 mg per injection
• Typical maintenance: 100 to 200 mg per injection, 2 to 3 times per week
• Higher dosing: Some practitioners prescribe up to 300 mg per injection for patients with higher needs

Advantages of SubQ

• Speed: Takes 30 seconds versus 2 to 4 hours for IV
• Cost: $25 to $75 per injection (purchased as multi-dose vials from compounding pharmacies)
• Convenience: Self-administered at home after initial training
• Fewer side effects: The slower absorption from subcutaneous tissue reduces the intensity of the NAD flush compared to IV

Limitations

SubQ injections deliver lower doses per session than IV. You cannot practically inject 500+ mg subcutaneously due to volume limitations and injection site discomfort. For patients who need high-dose protocols (addiction recovery, severe neurological conditions), IV remains the standard approach.

Injection site reactions are common: redness, mild stinging, and occasional bruising. These are typically mild and resolve within 30 minutes to a few hours. Rotating injection sites minimizes discomfort.

Compounded NAD+ for injection is prepared by compounding pharmacies, which the FDA does not review for safety or effectiveness before sale. The guide to NAD+ injections covers technique, storage and sourcing questions to raise with a prescriber.

Oral NAD+ Precursors: NMN and NR

Oral supplementation is the most accessible and affordable route. Since NAD+ itself breaks down in the gut, supplements use precursor molecules that get converted to NAD+ after absorption.

NMN (Nicotinamide Mononucleotide)

NMN is one enzymatic step away from NAD+ in the biosynthesis pathway. It is converted to NAD+ by the enzyme NMNAT. Research by Yoshino and colleagues at Washington University demonstrated that oral NMN supplementation increased NAD+ levels in humans and improved muscle insulin sensitivity in prediabetic women [4].

• Typical dose: 250 to 1,000 mg daily
• Common starting dose: 250 to 500 mg daily
• Timing: Morning on an empty stomach (or with a light meal)
• Forms: Capsules, sublingual powder, liposomal liquid

Sublingual NMN may offer better bioavailability than capsules by partially bypassing first-pass liver metabolism, though head-to-head human studies comparing routes are still limited [5].

NR (Nicotinamide Riboside)

NR is two enzymatic steps from NAD+ and was the first NAD+ precursor to gain significant commercial traction (sold as Niagen by ChromaDex). Multiple human studies have confirmed that NR supplementation raises blood NAD+ levels [6].

• Typical dose: 250 to 600 mg daily
• Common dose: 300 mg once or twice daily
• Timing: Morning, with or without food
• Forms: Capsules (most common)

How much NAD+ should you take per day?

Daily NAD+ dosing applies to the oral precursors, not to IV NAD+. A common daily dose is 250 to 1,000 mg of NMN, usually starting at 250 to 500 mg, or 250 to 600 mg of NR, often taken as 300 mg once or twice a day. Martens and colleagues (2018) used 1,000 mg of NR per day in healthy older adults and reported it was well tolerated [6].

NMN vs. NR: Which Is Better?

Factor	NMN	NR
Steps to NAD+	1 (NMN to NAD+ via NMNAT)	2 (NR to NMN to NAD+)
Human studies	Growing (Yoshino et al. 2021, others)	More established (Martens et al. 2018, others)
NAD+ elevation	Demonstrated in humans	Demonstrated in humans
Typical dose	250 to 1,000 mg/day	250 to 600 mg/day
Cost per month	$30 to $90	$30 to $60
FDA status	Supplement (GRAS status debated)	Supplement with NDI notification

Both raise NAD+ levels in humans. NMN is one step closer to NAD+ in the biosynthesis pathway, which some researchers argue makes it more efficient. NR has a longer track record of published human trials. In practice, many patients and practitioners treat them as roughly interchangeable for NAD+ support. Some people rotate or combine them [5][6].

A closer comparison of absorption, trial data and dosing sits in NMN vs. NR compared, and the trade-offs between infusions and capsules are laid out in NAD+ IV versus oral supplements.

Condition-Specific Dosing Protocols

Condition-specific NAD+ protocols are built from clinic experience, small pilot studies and precursor trials rather than large randomized trials. The doses below describe what clinics commonly use; they are not evidence that NAD+ treats any of these conditions.

Anti-Aging and General Longevity

• Oral: NMN 500 mg/day or NR 300 mg twice daily as baseline
• Optional boost: IV NAD+ 250 to 500 mg once monthly or quarterly
• This is the most common protocol for people who want to maintain NAD+ levels over time without aggressive clinical intervention

Cognitive Support and Brain Fog

• Loading: IV NAD+ 500 mg, 2 to 3 sessions over 1 week
• Maintenance: SubQ 100 to 200 mg, 2 to 3x/week, or oral NMN 500 to 1,000 mg/day
• Pair with: Omega-3s, B vitamins, adequate sleep

For brain fog after a head injury, higher IV ranges of 750 to 1,000 mg are used in some clinics, and a neurologist should be involved. The traumatic brain injury condition page outlines the conventional and adjunct options patients usually weigh.

Addiction Recovery

• Loading: IV NAD+ 1,000 to 1,500 mg daily for 7 to 10 days
• Step-down: IV 500 mg 2x/week for 2 weeks
• Maintenance: SubQ 100 to 200 mg 2 to 3x/week, or IV 500 mg monthly
• Note: Addiction protocols use the highest NAD+ doses and require clinical supervision [3]

NAD+ is not an FDA approved treatment for substance use disorder, and it does not replace medications for opioid or alcohol use disorder or a structured program. See the addiction treatment guide for how these approaches fit together.

Chronic Fatigue and Long COVID

• Loading: IV NAD+ 500 to 750 mg, 3 to 4 sessions over 2 weeks
• Maintenance: SubQ 100 to 200 mg, 2x/week, plus oral NMN 500 mg/day
• Many patients report noticeable energy improvements within the first 2 to 3 IV sessions

Those reports are anecdotal, and controlled data for NAD+ in chronic fatigue syndrome (ME/CFS) and long COVID are still limited. Clinicians often start people with post-exertional malaise at the low end of the range.

Athletic Performance and Recovery

• Oral: NMN 500 to 1,000 mg/day (taken in the morning)
• Optional: IV NAD+ 250 to 500 mg before major competitions or during heavy training blocks
• Research by Liao and colleagues showed NMN supplementation improved aerobic capacity in recreational runners [7]

Side Effects and Safety

IV NAD+: The main side effect is discomfort during infusion (chest tightness, nausea, flushing) when the drip rate is too fast. These symptoms resolve immediately when the rate is reduced. No serious adverse events have been reported in clinical use [3].

SubQ injections: Injection site redness and stinging are common. Rotating sites reduces this. Some patients report a brief wave of nausea after injection.

Oral NMN/NR: Generally well-tolerated. The most commonly reported side effect is mild GI discomfort (nausea, bloating) at higher doses. Human safety studies on NR at doses up to 1,000 mg/day and NMN at doses up to 1,250 mg/day have shown no significant adverse effects [4][6].

Long-term safety data for repeated high-dose IV NAD+ are thin, because the published human infusion work consists of small pilot studies such as Grant et al. (2019). People who are pregnant or breastfeeding, who have heart, liver or kidney disease, or who are in active cancer treatment should raise NAD+ dosing with their own physician before starting.

How to Choose Your Protocol

The right protocol depends on your goals, budget, and willingness to sit through IV sessions or self-inject.

• Budget-conscious, maintenance focus: Start with oral NMN (500 mg/day) or NR (300 mg 2x/day). This is the simplest and most affordable approach.
• Want faster results: Do a loading series of 3 to 4 IV sessions at 500 mg, then maintain with oral supplements and/or SubQ injections.
• Dealing with a specific condition: Work with a practitioner who can tailor IV dosing to your situation, then step down to a maintenance protocol you can sustain long-term.
• Athletes: Oral NMN at 500 to 1,000 mg/day is the most practical daily protocol. Add IV sessions during intense training blocks if budget allows.

When comparing infusion providers, ask who writes the order, what starting dose they use, how they adjust the drip rate, and where the NAD+ is compounded. The NAD+ IV clinic listings are free for patients to use; Featured slots there are labeled and capped, and Verified means a clinic passed credential checks, not that it paid. Being listed is not an endorsement.

Frequently asked questions

What is the standard NAD+ dosage?

The standard NAD+ dosage is 250 to 500 mg per IV session for general wellness, with clinics using 750 to 1,500 mg for neurological and addiction protocols. Subcutaneous injections are usually 50 to 200 mg two to three times per week. Oral precursors are dosed daily: NMN at 250 to 1,000 mg or NR at 250 to 600 mg. No dose is FDA approved for these uses, so a prescriber sets it.

What does a 250 mg NAD+ starter IV involve?

A 250 mg NAD+ starter IV is the usual first infusion and typically takes 1.5 to 2 hours. The nurse starts the drip slowly and raises the rate until mild flushing, nausea or chest tightness appears, then slows it down. Those symptoms fade quickly when the rate drops. If the first session goes well, later sessions often move up to 500 mg.

How often should you get NAD+ IV therapy?

Most clinics give NAD+ IV therapy as a loading series of 3 to 6 sessions over 1 to 2 weeks, then move to maintenance infusions of 250 to 500 mg once a month or once a quarter. Addiction protocols are more intensive, with daily infusions for 7 to 10 days under supervision. These schedules come from clinic practice, not from trials comparing frequencies.

How much NAD+ should I take per day?

Daily dosing applies to oral NAD+ precursors. A typical daily dose is 250 to 1,000 mg of NMN, often starting at 250 to 500 mg in the morning, or 250 to 600 mg of NR, commonly 300 mg once or twice daily. Martens et al. (2018) found 1,000 mg of NR per day well tolerated in older adults. IV NAD+ is not given daily outside addiction protocols.

Is a subcutaneous NAD+ injection as strong as an IV?

A subcutaneous NAD+ injection delivers a much smaller dose than an IV, usually 50 to 200 mg compared with 250 to 1,500 mg per infusion. Injections bypass the gut and absorb more slowly, which tends to soften the flushing that fast IV drips cause. They suit maintenance between infusions, while IV remains the route used for high-dose protocols such as addiction recovery.

Is NAD+ IV therapy covered by insurance?

NAD+ IV therapy is not covered by insurance and is paid in cash at infusion and integrative clinics. It has no FDA approved indication for aging, fatigue, brain fog or addiction, which is why insurers treat it as elective. Many patients reduce the overall cost by using IV only for a loading phase and switching to subcutaneous injections or oral NMN or NR for maintenance.

The Bottom Line

NAD+ dosing is not one-size-fits-all. IV infusions at 250 to 1,500 mg deliver the highest immediate bioavailability but come with high cost and long session times. SubQ injections at 100 to 200 mg offer a practical middle ground for regular dosing. Oral NMN (250 to 1,000 mg/day) and NR (250 to 600 mg/day) provide accessible daily support at a fraction of the cost.

For most people, the smartest approach is a hybrid: use IV for a loading phase when you want to rapidly boost levels, then maintain with SubQ or oral protocols. The specific doses depend on what you are treating, and a qualified practitioner can help you dial in the right numbers. For a full overview of NAD+ therapy and its applications, see our NAD+ IV therapy guide. For help choosing an oral supplement, see our best NAD+ supplement guide.

Related Reading

• NAD+ IV Therapy: The Complete Guide
• Best NAD+ Supplements
• Anti-Aging Supplements Guide

Sources

1. Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208-1213. ↩
2. Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018;27(3):529-547. ↩
3. Grant R, Berg J, et al. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD+. Front Aging Neurosci. 2019;11:257. ↩
4. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. ↩
5. Poddar SK, Sifat AE, Haque S, et al. Nicotinamide mononucleotide (NMN) supplementation promotes neurovascular rejuvenation. GeroScience. 2020;42(2):527-546. ↩
6. Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9:1286. ↩
7. Liao B, Zhao Y, Wang D, Zhang X, Hao X, Hu M. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners. J Int Soc Sports Nutr. 2021;18(1):54. ↩